New York City, New York Jun 29, 2021 (Issuewire.com) – EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, and Manhattan BioSolutions, an emerging biotechnology company developing immunoregulatory therapies for the treatment of metastatic cancers, have been awarded a grant from the University at Buffalo Center for […]
Mbio2018
12 posts
New York City, New York Feb 23, 2021 (Issuewire.com) – Manhattan BioSolutions, Inc, an emerging biotechnology company focused on the discovery of immunoregulatory therapies for the treatment of metastatic cancers, today announced positive preclinical data from its in vivo efficacy study in a mouse model of bladder cancer. These data validate the key advantages […]
NEW YORK, NEW YORK, UNITED STATES, January 13, 2021 – Manhattan BioSolutions, Inc. (MABS), an emerging biotechnology company focused on the discovery of the immunoregulatory therapies for the treatment of metastatic cancers, today announced that it will be participating at the “ACCESS CHINA Forum @ JPM WEEK 2021” which will […]
NEW YORK, NEW YORK, UNITED STATES, September 9, 2020 /EINPresswire.com/ — Manhattan BioSolutions, a biotechnology company focused on the discovery of the next-generation therapies for the treatment of cancer and inflammatory diseases, has been awarded a Phase I SBIR grant by the National Science Foundation (NSF) entitled “Genetically Engineered BCG […]
New York, NY August 25, 2020—EVQLV, Inc., an artificial intelligence-enabled technology company accelerating biologics discovery, announced today a strategic research collaboration with Manhattan BioSolutions, Inc., a biotechnology company focused on developing next-generation therapies for cancer and inflammatory diseases. Through the collaboration, the companies will jointly discover differentiated antibody therapeutics for […]
New York, NY, May 27, 2020 – Manhattan BioSolutions, Inc. (MBS), a biotechnology company focused on the discovery of the next-generation therapies for the treatment or prevention of cancer, today announced that the company has entered into an agreement with the Research Foundation for the State University of New York, […]
San Diego, CA, May 12, 2020—Nascent Biotech, Inc (OTCQB: NBIO), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat cancers and viral infections, and Manhattan BioSolutions, Inc., a biotechnology company focused on the discovery of the next-generation therapies for the treatment of cancer and inflammatory diseases, today announced […]
https://projectreporter.nih.gov/project_info_description.cfm?aid=9623199&icde=51409496&ddparam=&ddvalue=&ddsub=&cr=1&csb=default&cs=ASC&pball= Project Number: 1R43CA228746-01A1 Title: NOVEL RECOMBINANT BCG FOR IMMUNOTHERAPY OF BLADDER CANCER
https://jlabs.jnjinnovation.com/quickfire-challenges/jlabs-nyc-quickfire-challenge#paragraph-5131 https://www.prnewswire.com/news-releases/johnson–johnson-innovation-opens-jlabs–nyc-in-collaboration-with-new-york-state-and-the-new-york-genome-center-300670313.html